Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
01 Jul 2019
Historique:
received: 07 09 2018
revised: 29 11 2018
accepted: 25 12 2018
pubmed: 21 2 2019
medline: 6 10 2020
entrez: 21 2 2019
Statut: ppublish

Résumé

The tumour, node and the metastasis (TNM) staging system for thymic epithelial tumours was adopted by the Union for International Cancer Control (UICC) in 2016. Although the T factor is defined by the invasive nature of a thymoma, tumour size is not considered. The aim of this study was to examine the clinical importance of tumour size using a nationwide retrospective database of cases treated from 1991 to 2010 compiled by the Japanese Association for Research of the Thymus. Tumour size was evaluated by the maximum diameter shown by computed tomography imaging prior to resection. Tumour size was available for 2083 thymoma patients undergoing upfront surgical treatment. The tumour size ranged from 0.6 to 19.4 cm (mean 5.1 cm, median 4.9 cm). Harrell's C-index was adopted to determine the cut-off value of the tumour size in 0.5-cm increments. The highest C-index value (0.7760) was obtained in terms of recurrence-free survival after the complete resection when the cut-off value was set at 5.0 cm. The 10-year recurrence-free survival rate was 93.8% in patients with a tumour ≤5.0 cm and 84.3% in patients with a tumour >5.0 cm (P < 0.0001). The highest C-index value (0.8885) in terms of disease-specific survival was obtained when the cut-off value was set at 8.0 cm. The 10-year disease-specific survival rate was 98.8% in patients with a tumour <8.0 cm and 90.1% in those with a tumour ≥8.0 cm (P < 0.0001). The Cox's proportional hazard model analysis showed that the tumour size and the TNM-based pathological stage were independent factors to determine both recurrence-free survival and disease-specific survival. Tumour size is an important prognostic factor and should be considered when determining the treatment strategy for thymoma patients.

Identifiants

pubmed: 30783650
pii: 5345111
doi: 10.1093/ejcts/ezz001
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

174-181

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Meinoshin Okumura (M)

Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Ichiro Yoshino (I)

Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.

Motoki Yano (M)

Division of Chest Surgery, Department of Surgery, Aichi Medical University, Aichi, Japan.

Shun-Ichi Watanabe (SI)

Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.

Masahiro Tsuboi (M)

Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan.

Kazuo Yoshida (K)

Department of Thoracic Surgery, Shinshu University School of Medicine, Matsumoto, Japan.

Hiroshi Date (H)

Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Kohei Yokoi (K)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Jun Nakajima (J)

Department of Thoracic Surgery, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Shin-Ichi Toyooka (SI)

Department of General Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.

Hisao Asamura (H)

Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Division of Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan.

Etsuo Miyaoka (E)

Department of Mathematics, Science University of Tokyo, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH